Sagimet Biosciences (SGMT) Income from Continuing Operations (2022 - 2026)

Sagimet Biosciences' Income from Continuing Operations history runs 5 years deep, the most recent figure standing at 10650000.0 for Q1 2026.

• In Q1 2026, Income from Continuing Operations rose 41.41% year-over-year to 10650000.0; the TTM figure through Mar 2026 stood at 43512000.0 (up 23.82% YoY), while the FY2025 annual figure was 51038000.0, down 12.01% from the prior year.
• Income from Continuing Operations was 10650000.0 for Q1 2026 at Sagimet Biosciences, down from 9568000.0 in the prior quarter.
• In the past five years, Income from Continuing Operations ranged from a high of 6357000.0 in Q3 2023 to a low of 18176000.0 in Q1 2025.
• Historically, Income from Continuing Operations has averaged 9806187.5 across 5 years, with a median of 8135000.0 in 2023.
• The sharpest annual moves came in 2025 and 2026: Income from Continuing Operations plunged 174.19% in 2025, then soared 41.41% in 2026.
• A 5-year view of Income from Continuing Operations shows it stood at 7195000.0 in 2022, then dropped by 13.3% to 8152000.0 in 2023, then sank by 98.74% to 16201000.0 in 2024, then soared by 40.94% to 9568000.0 in 2025, then dropped by 11.31% to 10650000.0 in 2026.
• The last three Income from Continuing Operations figures came in at 10650000.0 (Q1 2026), 9568000.0 (Q4 2025), and 12908000.0 (Q3 2025), per Business Quant data.